The present invention pertains to a short acting NO donor for use in a method of reducing side effects of a treatment with said short acting NO donor, comprising administering during a defined time period a gradually increasing amount of said short acting NO donor in an intermitting manner. The present invention is further directed to a short acting NO donor for use in a method for the prevention or treatment of an arterial insufficiency, wherein the NO donor is administered in an intermitting manner, and wherein during the initial phase of the administration, the amount of said short acting NO donor is gradually increased.

The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate.

The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate.

The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate.

The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The method comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.

The present application relates to use of a nitric oxide releasing agent in the preparation of a medicament for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor. The present application further provides a method for preventing or treating diseases or disorders associated with administration of a VEGFR inhibitor and/or VEGF inhibitor in a subject. The method comprise administering, to a subject in need, a prophylactically or therapeutically effective amount of the nitric oxide releasing agent.

The present invention comprises compounds of formula (I): where R.sup.1 may be PEG or other polymeric moieties. For example, R.sup.1 may be repeating PEG units (CH.sub.2CH.sub.2O).sub.n, wherein n=1-455. R.sup.1 may also be other polymeric moieties of varying sizes and structures, for example, R.sup.1 may be poly(glycolide), poly(lactic acid), poly(lactide), poly(caprolactone), poly(lactide-co-caprolactone), poly(lactide-co-glycolide), or poly(lactic acid)-butanol. One or more embodiments of the invention may also relate to injectable pharmaceutical compositions comprising polymer conjugated monomethyl fumarate, and methods for treating relapsing-remitting multiple sclerosis and psoriasis.

##STR00001##

Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.

Compounds, compositions, and formulations, and accompanying methods useful for treating disorders arising from oxidative DNA damage, including oxidative DNA damage resulting from ionizing radiation or other therapy are described herein.

The present invention relates to compressed tablets comprising 3-nitrooxypropanol or derivatives thereof and a gluten as well as to the production of such tablets.